Final Exam Flashcards
MOA of ACE inhibitors
Blocks ACE which directly prevents:
- conversion of AT`1 to AT2
- breakdown of bradykinin
Pts with HT have more renin and AT in blood so ACE inhibitors work really well in these pts
Angiotensin II receptor:
- G-protein coupled receptor located on plasma membrane
- Mediates major biological function of AT2
- Located in vascular smooth muscle of vessels, brain, and adrenal gland
Antiotensin II type 1 receptor
Angiotensin II receptor:
- mainly present in fetus
- less abundant in adults
- functions are poorly understood
Angiotensin II type 2 receptor
Renin-Angiotensin Cycle
Describe the resulting effects after kidneys respond to decreased BP and renal blood flow…
Kidney’s sense decreased renal blood flow, decreased BP, or triggered by Beta -1 activation and kidneys release renin. Renin converts angiotensinogen to angiotensin I and ACE converts angiotensin I –> angiotensin II which results in:
Blood vessels - increase smooth muscle contraction & PR
Adrenal Gland (medulla) - increase release of NE & Epi (mostly Epi) which causes same effects as in blood vessels above AND increase HR, contractility, & CO
Adrenal Gland (cortex) - increases aldosterone release –> increases Na+ & H2O reabsorption (increases K+ secretion)
Post Pituitary Gland - increase vasopressin release –> increases water reabsorption
Hypothalamus - increases thirst
ALL THESE EFFECTS LEAD TO INCREASED BLOOD VOLUME AND BLOOD PRESSURE
ACE inhibitor AE
- dry cough
- angioedema
- rash
- hyperkalemia-from reduction in aldosterone (b/c aldosterone responsible for increasing secretion of K+)
- inflammation
- fetotoxicity-crosses placenta, don’t give during pregnancy
- taste dysfunction
Captopril
- ACE inhibitor
- Tx of HT (not 1st option), HF (1st line drug), MI
Lisinopril
- ACE inhibitor
- Tx of HT (not 1st option), HF (1st line drug), MI
Fosinopril, Enalapril, Moexipril
- ACE inhibitor
- Tx of HT (not 1st option), HF (1st line drug), MI
- Prodrug
Losartan
- Angiotensin II Receptor Blocker
- Tx of HT
- Prototype one of the 1st marketed AII antagonists
- orally active
- less dry cough SE b/c bradykinin and PGE2 levels not affected
Valsartan
- Angiotensin II Receptor Blocker
- Tx of HT
- one of the 1st marketed AII antagonists
- orally active
- less dry cough SE b/c bradykinin and PGE2 levels not affected
Telmisartan, Irbesartan, Candesartan, Eprosartan
- Angiotensin II Receptor Blocker
- Tx of HT
- less dry cough SE b/c bradykinin and PGE2 levels not affected
- newer and longer DOA than Losartan & Valsartan
- better PK profile
Aliskiren
- Renin inhibitor
- Tx of essential HT
- -Effective in lowering BP (esp in combo with hydrochlorothiazide)
- no effect on bradykinin metabolism
- no evidence of bradykinin-mediated SE (dry cough, angioedema, rash, etc.)
- orally active
- long DOA
Fibroblast Growth Factor 23 (FGF-23)
-protein produced by osteoblasts and osteoclasts
Vitamin D
-steroid produced in the skin from UV radiation; found in food & supplements
Etidronate
- older Bisphosphonate
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
- less GI problems than other bisphosphonates
Pamidronate
- older Bisphosphonate
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
Alendronate (Fosamax)
- older Bisphosphonate
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
- contraindicated in pts with active upper GI disease; risk of esophageal irritation
Risedronate
- newer Bisphosphonate
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
Tiludronate
- newer Bisphosphonate
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
Ibandronate (Boniva)
- newer Bisphosphonate
- Injection (~3x/yr); potent
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
Zoledronate
- newer Bisphosphonate
- Injection (once per year)
- Tx of Osteoporosis
- inhibits osteoclast activity
- has affinity for areas of active remodeling
- Bisphosphonates are the most appropriate INITIAL TX for women with osteoporosis
Raloxifene
- Selective estrogen receptor modulators (SERMS)
- approved for prevention & Tx of osteoporosis
- protects against spine, but not hip fractures
- reduces breast cancer risk
- more activity in bone than breast tissue
- best choice for pts susceptible to vertebral fractures
Estrogen/Progestin therapy
- No longer 1st line Tx for osteoporosis
- only moderately effective in Tx osteoporosis (used more for pre/postmenopausal women)
- still option for pts contraindicated from or intolerant to bisphosphonates or raloxifene
PTH (Teriparatide)
- represents a portion of PTH
- stimulates new bone formation and reduces risk of fractures
- requires expensive, daily SQ Inj
- stops working as soon as you stop taking it
- Increase effectiveness of PTH by taking Thiazide diuretic/restricting Na+ intake which can reduce renal Ca+2 excretion
Calcitonin
- lowers plasma Ca+2 (by using available Ca+2 in blood to form more bone)
- inhibits osteoclast bone reabsorption (breakdown of bone)
- unique role in acute Tx of osteoporotic fracture - may speed up healing; analgesic
Ergonovine
- Ergot alkaloid
- Tx of postpartum bleeding
- MOA: 5-HT agonist > alpha agonist
Ergotamine
- Ergot alkaloid
- Tx of migraine HA (given just prior to onset)
- MOA: 5-HT agonist, alpha agonist